Literature DB >> 26808121

Long-Term Drug-Free Remission and Visual Outcomes in Sympathetic Ophthalmia.

Abhishek R Payal1,2,3, C Stephen Foster1,2,4.   

Abstract

PURPOSE: To assess corticosteroid- and immunosuppressive therapy (IST)-free long-term remission in the treatment of patients with sympathetic ophthalmia (SO), a vision-robbing disease that can span a lifetime.
METHODS: The medical records of 19 patients with SO aged 16.1 to 94.95 years (median age 58.56 years) with median follow-up of 7.10 years (mean, 6.41; range, 2.5 to 8.63 years) were retrospectively examined.
RESULTS: All patients achieved control of inflammation, 13 of them for 2 years or more. Three (15.78%) of the 19 patients maintained remission without IST and corticosteroids for more than 5 years with vision of 20/25 or better in the sympathizing eye. Thirteen patients (68.42%) were inactive on IST or corticosteroids or in combination therapy. Eleven patients (57.9%) maintained visual acuity of 20/40 or better at the end of follow-up.
CONCLUSION: Even with a devastating and possibly lifelong disease like sympathetic ophthalmia, long-term remission off all IST and corticosteroids, and perhaps even cure, is possible.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26808121     DOI: 10.3109/09273948.2015.1092557

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  2 in total

1.  Dexamethasone Implant as Sole Therapy in Sympathetic Ophthalmia.

Authors:  Ahmad M Mansour
Journal:  Case Rep Ophthalmol       Date:  2018-05-22

2.  Sympathetic Ophthalmia: Experience from a Tertiary Care Center in Northern India.

Authors:  Rohan Chawla; Monika Kapoor; Aditi Mehta; Koushik Tripathy; Rajpal Vohra; Pradeep Venkatesh
Journal:  J Ophthalmic Vis Res       Date:  2018 Oct-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.